Sun Pharmaceutical Industries Ltd. and Ranbaxy Laboratories Ltd announced on 9th December that they have received the order of the Competition Commission of India (“CCI”) dated December 5, 2014(“Order”) by which CCI has approved the acquisition of Ranbaxy by Sun Pharma, subject to compliance with certain conditions.
AstraZeneca announced that MOVENTIG® (naloxegol) has been granted Marketing Authorisation by the European Commission (EC) for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). MOVENTIG is the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) to be approved in the European Union (EU).
(1st December, 2014); Medicines for Malaria Venture (MMV) signs collab oration agreements with two Indian pharmaceutical companies, Cipla Limited and Strides Arcolab Limited for the development of rectal artesunate for pre - referral treatment of children with severe malaria.
(26th November, 2014); Kerala based natural drug company, Arjuna Natural Extracts Ltd, got US patent of turmeric extract for treatment of Alzheimers disease. BCM-95, has received a US patent (US Patent No. 8859020) for a composition for the treatment of Alzheimers disease comprising curcuminoid mixture and added essential oil of turmeric. The patent also covers method of making the composition.
(12th November, 2014); Brodalumab, a novel psoriasis drug from colloboration of Amgen and Astrazeneca shown superior results in compare to Stelara® (ustekinumab) in head to head trials. The trial conducated on moderate-to-severe plaque psoriasis which met its primary endpoints when compared with both Stelara and placebo at week 12. Brodalumab was shown to be superior to Stelara on the primary endpoint of achieving total clearance of skin disease, as measured by the Psoriasis Area Severity Index (PASI 100).
(11th November, 2014); ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, announced that it has been awarded a project by the US Food & Drug Administration (FDA) to develop an industry-standard Patient Reported Outcome (PRO) measure that can be used in anti-bacterial drug development trials for hospital-acquired bacterial pneumonia (HABP).
[adsense:336x280:8701650588]
(11th November, 2014); Pharma Major Lupin Limited (Lupin) announced that it has received final approval for its Celecoxib Capsules, 50 mg from the United States Food and Drugs Administration (FDA) to market a generic version of G.D. Searle LLC’s (a subsidiary of Pfizer Inc.) Celebrex® Capsules 50 mg. Lupin also received tentative approvals for its Celecoxib capsules 100 mg, 200 mg and 400 mg strengths from the FDA.
(6th November, 2014; Business Wire India); Asia’s leading Discovery Research and Development organization, GVK BIO, announced the signing of a definitive agreement to acquire Vanta Bioscience, a full service preclinical GLP toxicology and safety assessment contract research organization operating out of Chennai, India.
(6th November, 2014); After successful 3rd clinical trial of Denue vaccine, Sanofi will file for registration of its vaccine candidate and, subject to regulatory approval, the world’s first dengue vaccine could be available in the second half of 2015.
(3rd November, 2014; Business Wire India); Biocon Ltd, Asia's premier biopharmaceuticals company, and U.S.-based CytoSorbents Corporation (OTCQB: CTSO) announced today that they have expanded the scope of their strategic partnership for CytoSorbents’ CytoSorb® cytokine reduction therapy to treat patients experiencing severe whole body inflammation, often called a Systemic Inflammatory Response Syndrome (SIRS). SIRS is caused by a wide range of life-threatening conditions seen in the intensive care unit and can also be caused by surgical interventions, particularly cardiac surgery.
[adsense:336x280:8701650588]
CLICK HERE TO SUBSCRIBE,
PHARMATUTOR's DAILY EMAILS
Do Not Forget to Verify
(Click on Subscription link in your inbox)
--------
